£20,000 in savings? Here's how investors can aim to turn that into a £1,680 second income overnight!
Take Legal & General Group (LSE:LGEN) as an example to consider. The insurance stock currently has an 8.4% payout, enough to start earning a £1,680 second income straight away. So what's the catch?
Investigating the yield
Generally speaking, a high dividend yield usually stems from a sudden drop in a stock price. Yet looking at Legal & General, that doesn't appear to be the case. In fact, the shares are actually up close to 15% in the last 12 months, and the company's been hiking shareholder payouts for the previous four years in a row.
That certainly makes the high yield seem like it's here to stay. But if that's the case, why aren't more investors jumping aboard to take advantage? Despite recent outperformance, there's growing concern among institutional investors that earnings will soon be under pressure.
Higher interest rates have made their long-term annuity financial products very popular in recent years, resulting in gold-rush-like growth. However, with rates coming down, demand's starting to slow. And in the meantime, all the recently-created annuity products issued during the higher interest rate environment now introduce long-duration risk exposure as well as miss-pricing risk.
This creates two problems: lower future growth and increased sensitivity to market shocks. And if Legal & General fails to hedge against these threats, earnings and, in turn, dividends could end up on the chopping block.
A risk worth taking?
The risk of earnings pressure is why Legal & General shares offer such a generous dividend today. However, despite these looming challenges, it's worth pointing out that the company's in a fair strong position at the moment.
The group maintains a Solvency II ratio of 217%. That's a very strong signal for robust financial health and provides a significant capital buffer against a market downturn.
At the same time, management's been busy executing numerous operational efficiency schemes to bolster margins across its key divisions.
For example, its Asset Management division's on track to steadily grow its operating profits to as high as £600m by 2028, versus the £401m achieved in 2024. And with the long-term demand for its Institutional Retirement products climbing on the back of an ageing population, dividends might be more sustainable than many investors currently think.
The bottom line
All things considered, Legal & General seems to offer a compelling case for investors seeking to build a second income stream. Admittedly, this comes paired with an elevated risk profile compared to other dividend opportunities in the FTSE 100.
But given the level of payout, investors with a higher risk tolerance may want to investigate further.
The post £20,000 in savings? Here's how investors can aim to turn that into a £1,680 second income overnight! appeared first on The Motley Fool UK.
More reading
5 Stocks For Trying To Build Wealth After 50
One Top Growth Stock from the Motley Fool
Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
Motley Fool UK 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Buffett Effect Still Holds as UnitedHealth Soars Through August
(Bloomberg) -- The Warren Buffett effect is proving true once again, spurring UnitedHealth Group Inc.'s reversal this month and giving the Dow Jones Industrial Average a push toward its first closing high since last year. Buffett's Berkshire Hathaway revealed last week that it bought a stake in the health insurer in the second quarter. UnitedHealth shares, which lost more than 50% from the start of 2025 through the end of July, have been on a tear this month, rising more than 20% in August alone and far outperforming any other company in the blue-chip index during that stretch. Why New York City Has a Fleet of New EVs From a Dead Carmaker Chicago Schools Seeks $1 Billion of Short-Term Debt as Cash Gone Trump Takes Second Swing at Cutting Housing Assistance for Immigrants A Photographer's Pipe Dream: Capturing New York's Vast Water System A London Apartment Tower With Echoes of Victorian Rail and Ancient Rome The stock has added more than 300 points to the Dow in August, accounting for more than 40% of its monthly gain. It has been a welcome boost for the stock-price-weighted benchmark, which hit an intraday record on Tuesday but has yet to close at a new all-time high and has been trounced by other major equity indexes, like the S&P 500 and Nasdaq 100, this year. 'There wasn't a single piece of good news basically this whole year specific to UnitedHealth,' Morningstar analyst Julie Utterback said. 'So having a company like Berkshire Hathaway investing competitively in a managed firm that was attractively valued, that's really a nice vote of confidence.' NOTE: Aug. 15, UnitedHealth Surges After Buffett, Tepper Bet on Turnaround (2) The 'Buffett Effect' essentially refers to a stock market phenomenon where share prices rise when the legendary investor takes a stake and fall when he exits a position. In this case it's notable because until very recently UnitedHealth was the biggest drag on the Dow this year. Then it reversed direction and quickly went from worst to first. 'Really Tough Year' 'Investors in UnitedHealth have had a really tough year,' said Utterback, who tracks the stock's decline to early December, when former executive Brian Thompson was fatally shot outside an investor conference in New York. The stock is still down 40% in 2025 and is trading at a little more than $300. Utterback has a buy rating and $400 price target on the shares. Thompson's murder, which was a targeted attack aimed at UnitedHealth's leadership, helped send the Dow on its longest losing streak since the 1970s. At the same time, the insurer's stock fell from the biggest weight in the 30-member index to seventh. But since the Berkshire Hathaway stake was revealed after the market closed on Aug. 14, Wall Street has turned incrementally positive on UnitedHealth. And more broadly, investors are starting to see some momentum from the entire health-care sector. Jonathan Krinsky, chief market technician at BTIG, says he's 'sticking with health care for a more defensive posture' and because it's the best-performing sector in the market in August.A As for UnitedHealth, it may be more attractive as a longer-term position. 'If you can take a five-year view (on UnitedHealth), you likely will do well,' analysts at BofA Securities wrote in a note to clients on Monday that was subtitled 'Berkshire is in, should you be?' The bank raised also its price target on the stock to $325 from $290. And when it comes to dragging the Dow to a new closing high, the company still needs some help. 'The rest of the stocks still need to be able to rally,' said Matt Maley, chief market strategist at Miller Tabak + Co., though he added that removing the biggest drag on the index is a positive sign. 'The DJIA is something the individual investor watches more closely than the pros.' Foreigners Are Buying US Homes Again While Americans Get Sidelined What Declining Cardboard Box Sales Tell Us About the US Economy Women's Earnings Never Really Recover After They Have Children Survived Bankruptcy. Next Up: Cultural Relevance? Americans Are Getting Priced Out of Homeownership at Record Rates ©2025 Bloomberg L.P. Sign in to access your portfolio
Yahoo
a few seconds ago
- Yahoo
āshibio licences vantictumab for rare bone disorder
Biotechnology company āshibio has entered an exclusive licencing agreement with Mereo BioPharma for the monoclonal antibody, vantictumab, to treat a rare bone disorder. The agreement aims to facilitate antibody development for the autosomal dominant osteopetrosis type 2 (ADO2) bone condition that currently lacks approved therapies. āshibio will oversee clinical development of vantictumab globally for both adult and paediatric patients. Mereo has granted exclusive rights to āshibio for the development and commercialisation in the US and other regions outside of Europe, where Mereo retains commercial rights. ADO2, also referred to as Albers-Schönberg disease, is a genetic disorder characterised by reduced osteoclast function, leading to dense and brittle bones. It is linked to mutations in the chloride channel 7 (CLCN7) gene, with an incidence rate of one in 20,000 births. Āshibio CEO Pankaj Bhargava stated: 'People living with autosomal dominant osteopetrosis type 2 face a lifetime of bone-related complications resulting in significant morbidity, multiple surgical procedures, chronic pain and impaired quality of life – yet patients have no approved therapy to address the disease. 'Bringing vantictumab into our pipeline reflects our commitment to advancing therapies for rare skeletal conditions and improving the lives of those affected by serious bone disorders.' Vantictumab functions by selectively binding to specific frizzled (Fzd) receptors and inhibiting Wnt (wingless-related integration) signalling pathways. Initially developed for cancer treatment, it has undergone clinical trials in oncology showing a favourable safety and pharmacokinetic profile. Previous studies have generated biomarker data that support the efficacy of vantictumab on osteoclast function, which aids in reducing risks associated with the clinical programme and allows āshibio to expedite the advancement of vantictumab into clinical trials for ADO2. "āshibio licences vantictumab for rare bone disorder" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
a few seconds ago
- Yahoo
Rising food bills put takeaways on hold
UK consumers are showing clear signs of restraint in their spending habits, with the latest Barclays Consumer Spending Report for July 2025 pointing to a slowdown in fast food and takeaway purchases. Overall spending in the eating and drinking category increased by just 0.8%, while bars, pubs, and clubs saw a 0.4% decline. Takeaway and fast food spending was virtually flat, inching up by only 0.1%, as households prioritise essentials over discretionary treats. Consumers cutting back as budgets tighten The findings underline how deeply the ongoing cost of living crisis continues to shape behaviour. More than half of consumers (51%) told Barclays they intend to cut discretionary spending, with 53% saying they will reduce fast food and takeaway purchases. Dining out is also under pressure, with 54% of people planning to eat at restaurants less often, while 42% are limiting what they spend on drinks at pubs and clubs. For many households, these decisions are not about choice but necessity. Rising rents, higher energy bills, and food price inflation have left little room for non-essential spending. Ordering a pizza or grabbing a quick meal from a fast food outlet is increasingly seen as a luxury rather than a cheap convenience. Grocery prices drive behaviour shifts Grocery inflation has eased slightly in recent months but remains high enough to pressure household budgets. Even small increases in weekly shopping bills force consumers to reconsider their priorities. Shoppers are focusing more on stretching their grocery spend, often opting for supermarket own-label products, discount retailers, and meal planning at home rather than spending on takeaways. This shift highlights how rising grocery costs have a double impact on consumer behaviour. On one hand, families are tightening control over food budgets at supermarkets; on the other, they are cutting back on fast food and dining out to make room for unavoidable grocery expenses. In effect, higher supermarket prices are squeezing discretionary food spend across the board. What retailers can learn from selective spending For retailers, the message is clear: shoppers want value, and they are willing to switch habits to find it. Discount grocers and supermarkets with strong own-label ranges are well placed to capture demand from budget-conscious households. Promotions that focus on meal solutions—such as affordable recipe bundles, family packs, or price-locked staples—can help retailers position themselves as allies in the battle against rising costs. Foodservice operators face a tougher landscape, but opportunities remain for those who can highlight value, convenience, or healthier alternatives. Loyalty schemes, bundled offers, and affordable menu options are likely to resonate most strongly with a cautious consumer base. Looking ahead The Barclays report confirms that fast food spending has stalled as households navigate the ongoing cost of living crisis. High grocery prices are forcing shoppers to think carefully about every pound, reshaping the way they spend on both everyday essentials and occasional treats. For retailers and food operators alike, the challenge is to adapt strategies that balance affordability with quality, helping consumers feel that their money goes further. Those who succeed will be best positioned to weather the selective spending environment and maintain relevance in a cautious market. "Rising food bills put takeaways on hold" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
